Equity Overview
Price & Market Data
Price: $0.0396
Daily Change: -$0.0044 / 11.11%
Daily Range: $0.038 - $0.0443
Market Cap: $1,715,648
Daily Volume: 183,536
Performance Metrics
1 Week: 9.70%
1 Month: -10.00%
3 Months: -20.80%
6 Months: -82.65%
1 Year: -91.75%
YTD: -12.00%
Company Details
Employees: 46
Sector: Health technology
Industry: Biotechnology
Country:
Details
Carisma Therapeutics, Inc., a biotechnology company, focuses on developing transformative therapies to treat liver fibrosis and cancer in the United States. Its product candidates include CT-2401, which is in preclinical trial for the treatment of liver fibrosis. The company also develops CT-1119, a mesothelin-targeted CAR-Monocyte that is in phase I clinical trial to treat patients with advanced mesothelin-positive solid tumors, including pancreatic cancer, ovarian cancer, lung cancer, mesothelioma, and others. In addition, it develops in vivo CAR-M cell therapy to treat solid tumors, including hepatocellular carcinoma. Carisma Therapeutics, Inc. has collaboration and license agreement with ModernaTX, Inc. to address oncology gene therapies. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. Carisma Therapeutics, Inc. was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.